1 citations
,
November 2011 in “Journal of AIDS & Clinical Research” Raltegravir may cause hair loss in some patients.
51 citations
,
August 2021 in “Turkish Journal of Medical Sciences” As of December 2021, the most effective COVID-19 treatments were monoclonal antibodies and possibly early-administered convalescent plasma, while several drugs were found ineffective or were still under evaluation.
176 citations
,
June 2016 in “PLoS ONE” Nucleic acid polymers can enhance antiviral responses and improve treatment outcomes for chronic hepatitis B.
6 citations
,
March 2022 in “Frontiers in drug discovery” Some small molecule antivirals show promise against COVID-19, but more research is needed to understand and improve them.
5 citations
,
December 2015 in “PubMed” Some gonadal hormone drugs can block filovirus entry into cells.
17 citations
,
February 2011 in “Expert Opinion on Drug Safety” Manage side effects of hepatitis C treatment with dose changes and medications, which may improve patient adherence and treatment success.
4 citations
,
April 2016 in “Journal of The American Academy of Dermatology” A patient with advanced kidney cancer and no hepatitis C developed skin inflammation due to a drug called interferon alpha-2a.
17 citations
,
August 2002 in “AIDS” Indinavir and ritonavir therapy can cause reversible hair loss.
3 citations
,
September 2020 in “Molecular Brain” The anti-viral drug Elvitegravir may protect brain cells from damage related to neurodegenerative diseases.
13 citations
,
September 2022 in “International Journal of Molecular Sciences” Five existing drugs may help fight Swine Acute Diarrhea Syndrome Coronavirus.
32 citations
,
October 2004 in “Pharmacotherapy” Peginterferon alfa-2b and ribavirin therapy for hepatitis C can cause serious side effects, some different from those reported in clinical trials.
5 citations
,
March 2021 in “Hepatitis Monthly” Tenofovir alafenamide fumarate is effective and safer for hepatitis B, with fewer side effects than tenofovir disoproxil fumarate.
1 citations
,
June 2020 in “Unisa Institutional Repository (University of South Africa)” Low power red laser with efavirenz can reduce HIV-1 infection to undetectable levels and improve diagnosis.
1 citations
,
May 2025 in “The Journal of Rheumatology” Careful monitoring is crucial to prevent JC virus reactivation in lupus patients treated with rituximab.
20 citations
,
July 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” Six existing drugs may help block virus entry in COVID-19.
1 citations
,
September 2022 in “Sudan Journal of Medical Sciences” Danoprevir, remdesivir, and saridegib may effectively inhibit SARS-CoV-2.
17 citations
,
January 1993 in “Journal of Gastroenterology and Hepatology” Interferon α‐2b can temporarily reduce hepatitis C virus and normalize liver enzyme levels.
8 citations
,
August 2022 in “Microorganisms” A standardized drug development platform is essential for efficient and effective drug repurposing, especially during pandemics.
11 citations
,
October 2023 in “ACS Pharmacology & Translational Science” Plant compounds may boost antiviral treatments.
36 citations
,
January 1993 in “Gut” High-dose interferon is effective for chronic hepatitis C but often causes flu-like symptoms.
3 citations
,
April 2021 in “bioRxiv (Cold Spring Harbor Laboratory)” New compounds effective against SARS-CoV-2 variants were identified using a rapid testing method with human lung cells.
January 2022 in “Drugs of Today” 7 citations
,
March 2002 in “AIDS” Indinavir, especially with vitamin A, may cause bone changes, but switching to nelfinavir can reduce these effects.
August 2025 in “Al-Iraqia Medical College Journal” Virus infection risk is linked to heat tolerance and size, but decreases with high humidity and mutation rates.
2 citations
,
July 2019 in “PLOS ONE” Certain genetic variations are linked to higher liver enzyme levels in patients treated for chronic hepatitis C with specific drugs.
August 2025 in “BMC Pharmacology and Toxicology” The LTF gene may help predict and manage nonspecific orbital inflammation.
2 citations
,
February 2018 in “International Research Journal of Pharmacy” Eclipta alba leaf alkaloids may help treat HIV by inhibiting the virus's activity.
36 citations
,
March 2014 in “Annals of the Rheumatic Diseases” Activating liver X receptors can reduce fibrosis by stopping certain immune cells from releasing harmful proteins.
1 citations
,
April 2025 in “Tropical Journal of Natural Product Research” Avicennia marina shows potential to treat Hepatitis C by targeting key proteins.
44 citations
,
June 2015 in “British Journal of Pharmacology” Betulinic acid can help treat hepatitis C by stopping virus replication.